NCT03364231

Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma

A Phase 2 Study to Assess the Efficacy and Safety of TGR-1202 (Umbralisib) Monotherapy in Patients With Non-Follicular Indolent Non-Hodgkin's Lymphoma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 21 (actual)
• Sponsor: TG Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This research study will evaluate the safety and efficacy of a study drug called Umbralisib (also known as TGR-1202) alone as a possible treatment for Waldenstrom's Macroglobulinemia that has come back or that has not responded to standard treatment.

Conditions

• Marginal Zone Lymphoma
• Waldenstrom Macroglobulinemia
• Non Follicular Indolent Non-Hodgkin Lymphoma

Interventions

Type	Name	Description
DRUG	Umbralisib	Oral Daily Dose

Timeline

• Start date: 2017-11-30
• Primary completion: 2022-02-15
• Completion: 2022-02-15
• First posted: 2017-12-06
• Last updated: 2023-06-23
• Results posted: 2023-06-23

Locations

4 sites across 1 country: United States

Regulatory

• FDA-regulated drug study